CITIUS ONCOLOGY, INC.
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
CTOR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US17331Y1091
- LEI:
- Country:
- United States of America
- Address:
- 11 COMMERCE DRIVE, 7016 CRANFORD
- Website:
- https://citiusonc.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. The company's primary product is LYMPHIR™ (denileukin diftitox-cxdl), a targeted immune therapy that received U.S. FDA approval in August 2024 for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). As a majority-owned subsidiary of Citius Pharmaceuticals, Inc., the company's strategy focuses on expediting development pathways for treatments with reduced clinical risks, leveraging intellectual property and regulatory exclusivity protections to secure competitive advantages. Citius Oncology is actively engaged in the commercial launch of LYMPHIR™.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CITIUS ONCOLOGY, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CITIUS ONCOLOGY, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CITIUS ONCOLOGY, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
